Fábio Trindade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fábio Trindade has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Rui Vitorino
RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal
32 shared publications - Rita Ferreira
University of Aveiro
19 shared publications - Adelino Ferreira Leite-Moreira
University of Porto
15 shared publications - Inês Falcão-Pires
University of Porto
15 shared publications - Francisco Amado
LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
9 shared publications - Antônio Soares Barros
RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
8 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Elsevier in JVS-Vascular Insights
- Vol. 4
Feasibility and short-term effects of a novel whole body limb elevation device (UZit) in patients with symptomatic chronic venous disease
- 14 July 2026
- Published by Elsevier in JVS-Vascular Insights
- Vol. 4
Open AccessFeasibility and short-term effects of a novel whole body limb elevation device (UZit) in patients with symptomatic chronic venous disease
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005451
Multiomics for Risk Stratification in Atherosclerotic Cardiovascular Disease
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide. Preventing ASCVD is of utmost importance; however, a large proportion of preventable cases is not discovered early enough to initiate relevant treatment. Risk stratification for ASCVD includes classical risk factors, such as sex, age, smoking habits, blood pressure, cholesterol levels, and diabetes. Current risk prediction models, including the Systematic Coronary Risk Evaluation 2 algorithms, are designed for individuals aged 40 to 69 years and relate to 10-year risk and not to lifetime risk, thereby being inaccurate for the young. Another problem is the underdiagnosis of events in women, thereby underestimating risk. Multiomics, encompassing genomics, epigenomics, transcriptomics, epitranscriptomics, proteomics, and metabolomics, offers new opportunities. Polygenic risk scores derived from genomic data may improve ASCVD risk classification. While genomic risk is established at inception, epigenomics captures the influence of environmental exposures over the lifespan through dynamic DNA modifications that regulate gene expression. Proteomics-based prediction reflects interactions between genetic inheritance, and modifiable and nonmodifiable influences. Transcriptomic analyses of carotid plaques have clustered human atherosclerotic lesions into distinct molecular subgroups, and changes in RNA methylation of circulating blood cells have been linked to clinical outcomes after ASCVD. Metabolomics identifies metabolic signatures, including lipid subclass alterations, amino acid imbalances, and inflammatory markers, all associated with cardiovascular disease incidence. In this review, we highlight current challenges, explore potential solutions, and discuss how integrating multiple omic layers through computational modeling (multiomics) could enhance patient stratification, optimize clinical management, and reduce the global burden of ASCVD.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005451
Open AccessMultiomics for Risk Stratification in Atherosclerotic Cardiovascular Disease
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide. Preventing ASCVD is of utmost importance; however, a large proportion of preventable cases is not discovered early enough to initiate relevant treatment. Risk stratification for ASCVD includes classical risk factors, such as sex, age, smoking habits, blood pressure, cholesterol levels, and diabetes. Current risk prediction models, including the Systematic Coronary Risk Evaluation 2 algorithms, are designed for individuals aged 40 to 69 years and relate to 10-year risk and not to lifetime risk, thereby being inaccurate for the young. Another problem is the underdiagnosis of events in women, thereby underestimating risk. Multiomics, encompassing genomics, epigenomics, transcriptomics, epitranscriptomics, proteomics, and metabolomics, offers new opportunities. Polygenic risk scores derived from genomic data may improve ASCVD risk classification. While genomic risk is established at inception, epigenomics captures the influence of environmental exposures over the lifespan through dynamic DNA modifications that regulate gene expression. Proteomics-based prediction reflects interactions between genetic inheritance, and modifiable and nonmodifiable influences. Transcriptomic analyses of carotid plaques have clustered human atherosclerotic lesions into distinct molecular subgroups, and changes in RNA methylation of circulating blood cells have been linked to clinical outcomes after ASCVD. Metabolomics identifies metabolic signatures, including lipid subclass alterations, amino acid imbalances, and inflammatory markers, all associated with cardiovascular disease incidence. In this review, we highlight current challenges, explore potential solutions, and discuss how integrating multiple omic layers through computational modeling (multiomics) could enhance patient stratification, optimize clinical management, and reduce the global burden of ASCVD.
- Open Access
- 6 October 2025
- Published by Springer Nature in Clinical Proteomics
- Vol. 22 (1) , 1-19
Dissecting sexual dimorphism in aortic valve stenosis by proteomics
Background: The treatment of aortic valve stenosis (AVS) remains limited to aortic valve replacement (AVR). No pharmacotherapy has yet proven efficacious, and its development is challenged by sexual dimorphism. Women display extensive valve fibrosis, and men present remarkably higher valve calcification. To accelerate the development of sex-personalised therapies, deeper molecular insights are needed. Hence, we aimed to characterise AVS sexual dimorphism using proteomics. Methods: Fifty surgically excised valves (50% women) were homogenised, and the proteins were quantified by LC-MS/MS. The influence of differentially expressed proteins (DEPs) in sexual dimorphism was appraised using bioinformatics. DEPs were validated using immunohistochemistry, qRT-PCR and ELISA, with 30 additional valves. Results: We quantified ~ 4,000 proteins and 76 DEPs between sexes. CD163, CD74, and NADPH oxidase-2 (NOX2) were more abundant in men’s valves and central in a protein-protein interaction network. Functional enrichment analysis (FEA) supported increased lipoprotein binding and macrophage activation in men’s valves, confirmed by increased CD74 + cell infiltration (immunohistochemistry). Aminopeptidase N, coagulation factor XIII, and metalloreductase STEAP4 were more abundant in men’s valves at the transcript and protein levels. FEA indicated a women-specific dysregulation of spliceosomal proteins that may dictate a pro-fibrotic phenotype, which was observed histologically. A higher glutathione peroxidase-1/NOX2 ratio (ELISA) was found in women, suggesting increased protection against oxidative stress. Conclusions: Proteomics confirms sexual dimorphism in AVS. Women displayed a higher degree of fibrotic remodelling, whereas men displayed greater immune cell infiltration and were less protected from oxidation, favouring calcification. Proteomics identified putative targets for a sex-personalised AVS modulation. Graphical We studied sexual dimorphism in aortic valve stenosis following a proteomic approach. Proteins were quantified by mass spectrometry and sex differences were uncovered by differential expression, network and pathway analyses. Some targets were selected for validation by PCR, immunohistochemistry and ELISA. Collectively, our experiments support a higher propensity for men’s valves to accumulate lipoproteins, red and white blood cells, with concomitantly greater activation of macrophages, particularly CD74+. Men’s valves also show a higher propensity for oxidative stress and calcification. Women’s valves are less prone to oxidative stress (higher GPX1/NOX2) but show a greater extent of fibrosis, which might result from an alternative splicing program that translates into a significant dysregulation of focal adhesion proteins. Some graphical elements were retrieved from Flaticon (https://www.flaticon.com/).
- 6 October 2025
- Published by Springer Nature in Clinical Proteomics
- Vol. 22 (1) , 1-19
Open AccessDissecting sexual dimorphism in aortic valve stenosis by proteomics
Background: The treatment of aortic valve stenosis (AVS) remains limited to aortic valve replacement (AVR). No pharmacotherapy has yet proven efficacious, and its development is challenged by sexual dimorphism. Women display extensive valve fibrosis, and men present remarkably higher valve calcification. To accelerate the development of sex-personalised therapies, deeper molecular insights are needed. Hence, we aimed to characterise AVS sexual dimorphism using proteomics. Methods: Fifty surgically excised valves (50% women) were homogenised, and the proteins were quantified by LC-MS/MS. The influence of differentially expressed proteins (DEPs) in sexual dimorphism was appraised using bioinformatics. DEPs were validated using immunohistochemistry, qRT-PCR and ELISA, with 30 additional valves. Results: We quantified ~ 4,000 proteins and 76 DEPs between sexes. CD163, CD74, and NADPH oxidase-2 (NOX2) were more abundant in men’s valves and central in a protein-protein interaction network. Functional enrichment analysis (FEA) supported increased lipoprotein binding and macrophage activation in men’s valves, confirmed by increased CD74 + cell infiltration (immunohistochemistry). Aminopeptidase N, coagulation factor XIII, and metalloreductase STEAP4 were more abundant in men’s valves at the transcript and protein levels. FEA indicated a women-specific dysregulation of spliceosomal proteins that may dictate a pro-fibrotic phenotype, which was observed histologically. A higher glutathione peroxidase-1/NOX2 ratio (ELISA) was found in women, suggesting increased protection against oxidative stress. Conclusions: Proteomics confirms sexual dimorphism in AVS. Women displayed a higher degree of fibrotic remodelling, whereas men displayed greater immune cell infiltration and were less protected from oxidation, favouring calcification. Proteomics identified putative targets for a sex-personalised AVS modulation. Graphical We studied sexual dimorphism in aortic valve stenosis following a proteomic approach. Proteins were quantified by mass spectrometry and sex differences were uncovered by differential expression, network and pathway analyses. Some targets were selected for validation by PCR, immunohistochemistry and ELISA. Collectively, our experiments support a higher propensity for men’s valves to accumulate lipoproteins, red and white blood cells, with concomitantly greater activation of macrophages, particularly CD74+. Men’s valves also show a higher propensity for oxidative stress and calcification. Women’s valves are less prone to oxidative stress (higher GPX1/NOX2) but show a greater extent of fibrosis, which might result from an alternative splicing program that translates into a significant dysregulation of focal adhesion proteins. Some graphical elements were retrieved from Flaticon (https://www.flaticon.com/).
- Open Access
- 5 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 4865-4874
Lipidomic Signature of Abdominal Aortic Aneurysm and Peripheral Artery Disease
Vascular diseases are powerful predictors of cardiovascular mortality, but they are typically under-recognized and undertreated. There is no effective treatment for either abdominal aortic aneurysm (AAA) or peripheral artery disease (PAD). Lipids are key molecules in cardiovascular diseases and good candidates for diagnosis, monitoring, and risk prediction; nonetheless, there is very limited information on the lipidomic profile of patients with AAA and PAD. We hypothesize that lipids can be used as important prognostic biomarkers of these diseases. To achieve this, we conducted a comprehensive C18 reversed-phase (RP) liquid chromatography-tandem mass spectrometry (LC-MS) lipidomic analysis of plasma from AAA and PAD patients undergoing open repair surgery, comparing their profiles with those of healthy controls. We observed a marked reduction in PAD and AAA of the relative abundances of (i) phospholipids bearing polyunsaturated fatty acids, primarily from the phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) classes, mostly due to oxidative degradation, and (ii) plasmalogen species of PC and PE, which serve as endogenous antioxidants. On the other side, SM and Cer increased in both pathologies. Our findings suggest a dysregulation of the lipid metabolism in AAA and PAD compared with healthy controls that deserves exploration to unravel putative biomarkers or disease hallmarks.
- 5 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 4865-4874
Open AccessLipidomic Signature of Abdominal Aortic Aneurysm and Peripheral Artery Disease
Vascular diseases are powerful predictors of cardiovascular mortality, but they are typically under-recognized and undertreated. There is no effective treatment for either abdominal aortic aneurysm (AAA) or peripheral artery disease (PAD). Lipids are key molecules in cardiovascular diseases and good candidates for diagnosis, monitoring, and risk prediction; nonetheless, there is very limited information on the lipidomic profile of patients with AAA and PAD. We hypothesize that lipids can be used as important prognostic biomarkers of these diseases. To achieve this, we conducted a comprehensive C18 reversed-phase (RP) liquid chromatography-tandem mass spectrometry (LC-MS) lipidomic analysis of plasma from AAA and PAD patients undergoing open repair surgery, comparing their profiles with those of healthy controls. We observed a marked reduction in PAD and AAA of the relative abundances of (i) phospholipids bearing polyunsaturated fatty acids, primarily from the phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) classes, mostly due to oxidative degradation, and (ii) plasmalogen species of PC and PE, which serve as endogenous antioxidants. On the other side, SM and Cer increased in both pathologies. Our findings suggest a dysregulation of the lipid metabolism in AAA and PAD compared with healthy controls that deserves exploration to unravel putative biomarkers or disease hallmarks.
- Open Access
- 6 July 2025
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 120 (5) , 1-28
Myocardial phosphoproteomics unveils a key role of DYRK1A in aortic valve replacement-induced reverse remodelling
Aortic valve stenosis (AVS) is a growing healthcare burden. Aortic valve replacement (AVR) remains the only effective treatment to eliminate pressure overload and triggers myocardial reverse remodelling (RR), with regression of hypertrophy, fibrosis and diastolic function normalisation. However, many patients show an incomplete RR, being at higher risk of death. We aimed to uncover pathways and new therapeutic targets for incomplete RR through myocardial (phospho)proteomics. AVS patients were categorised based on left ventricle mass regression (LVM): complete RR (≥ 15%) or incomplete RR (≤ 5%). 83 myocardial proteins were dysregulated through LC–MS/MS. Gene ontology enrichment analysis identified inflammation, complement and immune system activation as priming events of an incomplete RR and a better mitochondrial function underscoring complete RR. Kinetic metabolic modelling corroborated the lower ATP production capacity of incomplete RR patients. To uncover therapeutic targets, kinases were predicted from phosphoproteome data. Casein kinase 2 and DYRK1A were among the most dysregulated kinases in RR. DYRK1A was found to be inversely correlated with LVM regression (r = − 0.62). DYRK1A functional role (passive, maximal tension and Ca2+ sensitivity) was evaluated in skinned cardiomyocytes from Dyrk1a +/- mice and from AVS patients upon incubation with this kinase. Cardiomyocytes from mutant mice showed increased myofilamentary stiffness in response to stretch. Also, the raised myofilamentary stiffness of cardiomyocytes isolated from incomplete RR was normalised upon incubation with DYRK1A. Better myocardial bioenergetics may underscore a complete LVM regression. In turn, complement and immune-inflammatory pathways activation prime an incomplete response to AVR. DYRK1A emerges as a surrogate target to treat myocardial stiffness-driven diastolic dysfunction.
- 6 July 2025
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 120 (5) , 1-28
Open AccessMyocardial phosphoproteomics unveils a key role of DYRK1A in aortic valve replacement-induced reverse remodelling
Aortic valve stenosis (AVS) is a growing healthcare burden. Aortic valve replacement (AVR) remains the only effective treatment to eliminate pressure overload and triggers myocardial reverse remodelling (RR), with regression of hypertrophy, fibrosis and diastolic function normalisation. However, many patients show an incomplete RR, being at higher risk of death. We aimed to uncover pathways and new therapeutic targets for incomplete RR through myocardial (phospho)proteomics. AVS patients were categorised based on left ventricle mass regression (LVM): complete RR (≥ 15%) or incomplete RR (≤ 5%). 83 myocardial proteins were dysregulated through LC–MS/MS. Gene ontology enrichment analysis identified inflammation, complement and immune system activation as priming events of an incomplete RR and a better mitochondrial function underscoring complete RR. Kinetic metabolic modelling corroborated the lower ATP production capacity of incomplete RR patients. To uncover therapeutic targets, kinases were predicted from phosphoproteome data. Casein kinase 2 and DYRK1A were among the most dysregulated kinases in RR. DYRK1A was found to be inversely correlated with LVM regression (r = − 0.62). DYRK1A functional role (passive, maximal tension and Ca2+ sensitivity) was evaluated in skinned cardiomyocytes from Dyrk1a +/- mice and from AVS patients upon incubation with this kinase. Cardiomyocytes from mutant mice showed increased myofilamentary stiffness in response to stretch. Also, the raised myofilamentary stiffness of cardiomyocytes isolated from incomplete RR was normalised upon incubation with DYRK1A. Better myocardial bioenergetics may underscore a complete LVM regression. In turn, complement and immune-inflammatory pathways activation prime an incomplete response to AVR. DYRK1A emerges as a surrogate target to treat myocardial stiffness-driven diastolic dysfunction.
- Open Access
- 16 June 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 13, 100460
Bioinformatics tools for drug repurposing: a tutorial using heart failure as a case study
- 16 June 2025
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 13, 100460
Open AccessBioinformatics tools for drug repurposing: a tutorial using heart failure as a case study
- Open Access
- 5 June 2025
- Published by Elsevier in Archives of Oral Biology
- Vol. 177, 106319
Salivary proteome and microbiome in pregnancy and postpartum: An exploratory study on the relation with arterial hypertension
- 5 June 2025
- Published by Elsevier in Archives of Oral Biology
- Vol. 177, 106319
Open AccessSalivary proteome and microbiome in pregnancy and postpartum: An exploratory study on the relation with arterial hypertension
- Open Access
The Role of Chlorella and Spirulina as Adjuvants of Cardiovascular Risk Factor Control: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Background/Objectives: Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). However, the available studies are limited in size and have used different outcomes. Methods: To gain power in assessing the impact of microalgae supplements on cardiovascular risk factors, we searched PubMed on 3 February 2023 for randomised controlled trials assessing the effects of Chlorella and Spirulina on modifiable cardiovascular risk factors. Results: We found 12 studies in Chlorella and 9 studies on Spirulina. Depending on the available outcomes, varying numbers of participants (Chlorella: 168 to 279; Spirulina: 101 to 299) were included. Our analysis showed that Chlorella supplementation had a neutral effect on BP and lipemia. On the other hand, Spirulina intake led to a significant reduction in diastolic BP (−0.42, 95% CI: −0.81 to −0.02, p = 0.04) but did not significantly affect lipemia indexes, despite a trend toward a reduction in total cholesterol (−0.17, 95% CI: −0.39 to 0.06, p = 0.15). This meta-analysis suggests Spirulina supplementation can be used as an adjuvant to control cardiometabolic risk factors, particularly for BP. However, the magnitude of this effect is small and of uncertain clinical significance. Conclusions: Further randomised trials are needed to better assess the potential of these supplements as adjuvants for the control of cardiovascular risk factors.
Open AccessThe Role of Chlorella and Spirulina as Adjuvants of Cardiovascular Risk Factor Control: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Background/Objectives: Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). However, the available studies are limited in size and have used different outcomes. Methods: To gain power in assessing the impact of microalgae supplements on cardiovascular risk factors, we searched PubMed on 3 February 2023 for randomised controlled trials assessing the effects of Chlorella and Spirulina on modifiable cardiovascular risk factors. Results: We found 12 studies in Chlorella and 9 studies on Spirulina. Depending on the available outcomes, varying numbers of participants (Chlorella: 168 to 279; Spirulina: 101 to 299) were included. Our analysis showed that Chlorella supplementation had a neutral effect on BP and lipemia. On the other hand, Spirulina intake led to a significant reduction in diastolic BP (−0.42, 95% CI: −0.81 to −0.02, p = 0.04) but did not significantly affect lipemia indexes, despite a trend toward a reduction in total cholesterol (−0.17, 95% CI: −0.39 to 0.06, p = 0.15). This meta-analysis suggests Spirulina supplementation can be used as an adjuvant to control cardiometabolic risk factors, particularly for BP. However, the magnitude of this effect is small and of uncertain clinical significance. Conclusions: Further randomised trials are needed to better assess the potential of these supplements as adjuvants for the control of cardiovascular risk factors.
- 4 June 2024
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 26 (7) , 1454-1479
Mechanisms of Myocardial Reverse Remodelling and Its Clinical Significance: A Scientific Statement of the ESC Working Group on Myocardial Function
Cardiovascular disease (CVD) is the leading cause of morbimortality in Europe and worldwide. CVD imposes a heterogeneous spectrum of cardiac remodelling, depending on the insult nature, that is, pressure or volume overload, ischaemia, arrhythmias, infection, pathogenic gene variant, or cardiotoxicity. Moreover, the progression of CVD-induced remodelling is influenced by sex, age, genetic background and comorbidities, impacting patients' outcomes and prognosis. Cardiac reverse remodelling (RR) is defined as any normative improvement in cardiac geometry and function, driven by therapeutic interventions and rarely occurring spontaneously. While RR is the outcome desired for most CVD treatments, they often only slow/halt its progression or modify risk factors, calling for novel and more timely RR approaches. Interventions triggering RR depend on the myocardial insult and include drugs (renin–angiotensin–aldosterone system inhibitors, beta-blockers, diuretics and sodium–glucose cotransporter 2 inhibitors), devices (cardiac resynchronization therapy, ventricular assist devices), surgeries (valve replacement, coronary artery bypass graft), or physiological responses (deconditioning, postpartum). Subsequently, cardiac RR is inferred from the degree of normalization of left ventricular mass, ejection fraction and end-diastolic/end-systolic volumes, whose extent often correlates with patients' prognosis. However, strategies aimed at achieving sustained cardiac improvement, predictive models assessing the extent of RR, or even clinical endpoints that allow for distinguishing complete from incomplete RR or adverse remodelling objectively, remain limited and controversial. This scientific statement aims to define RR, clarify its underlying (patho)physiologic mechanisms and address (non)pharmacological options and promising strategies to promote RR, focusing on the left heart. We highlight the predictors of the extent of RR and review the prognostic significance/impact of incomplete RR/adverse remodelling. Lastly, we present an overview of RR animal models and potential future strategies under pre-clinical evaluation.
- 4 June 2024
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 26 (7) , 1454-1479
Mechanisms of Myocardial Reverse Remodelling and Its Clinical Significance: A Scientific Statement of the ESC Working Group on Myocardial Function
Cardiovascular disease (CVD) is the leading cause of morbimortality in Europe and worldwide. CVD imposes a heterogeneous spectrum of cardiac remodelling, depending on the insult nature, that is, pressure or volume overload, ischaemia, arrhythmias, infection, pathogenic gene variant, or cardiotoxicity. Moreover, the progression of CVD-induced remodelling is influenced by sex, age, genetic background and comorbidities, impacting patients' outcomes and prognosis. Cardiac reverse remodelling (RR) is defined as any normative improvement in cardiac geometry and function, driven by therapeutic interventions and rarely occurring spontaneously. While RR is the outcome desired for most CVD treatments, they often only slow/halt its progression or modify risk factors, calling for novel and more timely RR approaches. Interventions triggering RR depend on the myocardial insult and include drugs (renin–angiotensin–aldosterone system inhibitors, beta-blockers, diuretics and sodium–glucose cotransporter 2 inhibitors), devices (cardiac resynchronization therapy, ventricular assist devices), surgeries (valve replacement, coronary artery bypass graft), or physiological responses (deconditioning, postpartum). Subsequently, cardiac RR is inferred from the degree of normalization of left ventricular mass, ejection fraction and end-diastolic/end-systolic volumes, whose extent often correlates with patients' prognosis. However, strategies aimed at achieving sustained cardiac improvement, predictive models assessing the extent of RR, or even clinical endpoints that allow for distinguishing complete from incomplete RR or adverse remodelling objectively, remain limited and controversial. This scientific statement aims to define RR, clarify its underlying (patho)physiologic mechanisms and address (non)pharmacological options and promising strategies to promote RR, focusing on the left heart. We highlight the predictors of the extent of RR and review the prognostic significance/impact of incomplete RR/adverse remodelling. Lastly, we present an overview of RR animal models and potential future strategies under pre-clinical evaluation.
- Open Access
- 23 January 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 966, 176336
Acute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction
- 23 January 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 966, 176336
Open AccessAcute and chronic effects of levosimendan in the ZSF1 obese rat model of heart failure with preserved ejection fraction